ClinicalTrials.gg
RecruitingNCT03842007Updated Aug 21, 2026

Understanding Mechanisms of Normal and Disordered Defecation

An interventional study of Rectal Barostat Study and Fecoflowmetry in Constipation, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-21.

Sponsored by Mayo Clinic · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Started Jan 2019; still recruiting 7 years 9 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
160
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Researchers are trying to better understand why constipation occurs and improve the tests for diagnosing these conditions.

Read the detailed description

Study includes a screening visit and a study day. During the initial screening visit for this study, subjects will complete three (3) questionnaires about their bowel symptoms, overall health, and anxiety and depression. A blood sample (about 4 tablespoons) will be drawn to study the relationship between genes and certain bowel habits. Subjects will be asked to provide a single stool sample to look at the bacteria in the stool.

Before the study, subjects will receive 1 to 2 Fleet's enemas to clean the rectum. After receiving the Fleet's enema (administered through a small plastic tube in the rectum), a swab attached to a small rectal catheter will be used to brush the lining of the rectum and obtain a stool specimen. Then, rectal and anal pressures will be measured by placing a small catheter (plastic tube) in the rectum, and withdrawing it slowly. Rectal sensation will be measured by inflating a small balloon in the rectum.

There are 2 procedures (rectal barostat study and fecomanoflowmetry), each of which lasts approximately 90 minutes. During the rectal barostat study, contractions will be recorded with a balloon inserted into the rectum and inflated. After the barostat study is completed, your rectum will be filled with a small amount of paste. Two thin catheters will be inserted into the anus to measure pressures and electrical activity (electromyography or EMG). Then, you will be asked to sit on a commode, contract (squeeze) your anal muscles, blow into a balloon, and expel the paste into the commode.

02

Conditions studied

  • Constipation

Browse trials for

03

In context

Constipation

1,046 studies on the registry are indexed under Constipation; 161 are open to participants now.

This study's planned enrollment of 160 is above the median of 75 across 884 interventional studies indexed under Constipation.

Browse Constipation studies →

Lead sponsor

Mayo Clinic is the lead sponsor of 3,269 studies on the registry; 672 are open to participants now.

Of its 452 completed or terminated interventional studies of FDA-regulated products, 321 (71%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female volunteers aged 18-80 years.
  • Able to provide written before participating in the study.
  • Able to communicate adequately with the investigator and to comply with the requirements for the entire study.
  • Individuals with chronic constipation for 1 year, with 2 or more of the following symptoms for 3 months or longer: \<3 bowel motions/week, straining ≥ 25% of time, hard or lumpy stools ≥ 25% of time, anal digitation ≥ 25% of time, incomplete evacuation ≥ 25% of time, feeling of anorectal blockage ≥ 25% of time.
  • Able to provide written informed consent before participating in the study.
  • Able to communicate adequately with the investigator and to comply with the requirements for the entire study.

Exclusion criteria

Exclusion Criteria

  • Clinical evidence of significant cardiovascular, respiratory, renal, hepatic, gastrointestinal, hematological, neurological, psychiatric or other disease that may interfere with the objectives of the study and/or pose safety concerns.
  • Current symptoms of a functional gastrointestinal disorder assessed by questionnaire.
  • Putative risk factors for pelvic floor trauma: i.e. six or more vaginal deliveries, birthweight >4500gms (macrosomia), or known 3rd or 4th degree perineal tear.
  • Medications that are likely to alter gastrointestinal motility: e.g., opiates and anticholinergic medications; a stable dose of thyroxine and low doses of tricyclic agents (e.g., up to amitriptyline (50 mg daily).
  • Active rectal inflammation, cancer; perianal sepsis; history of pelvic radiation, rectosigmoid surgery or inflammatory bowel disease.*
  • Anxiety or depression as assessed by the Hospital Anxiety and Depression Questionnaire.
  • Pregnant women, prisoners and institutionalized individuals.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
160 participants (estimated)

Study arms

  • Active comparator
    Healthy Individuals

    Sixty healthy individuals (20 men and 40 women) will undergo an anorectal study which comprises of a rectal barostat study followed by fecoflowmetry

    Diagnostic Test: Rectal Barostat Study · Diagnostic Test: Fecoflowmetry

  • Active comparator
    Constipated Individuals

    60 constipated individuals (20 men and 40 women) will undergo an anorectal study which comprises of a rectal barostat study followed by fecoflowmetry

    Diagnostic Test: Rectal Barostat Study · Diagnostic Test: Fecoflowmetry

Interventions

  • Diagnostic testRectal Barostat Study

    Contractions will be recorded with a balloon inserted into the rectum and inflated

  • Diagnostic testFecoflowmetry

    Rectum will be filled with a small amount of paste.Two thin catheters will be inserted into the anus to measure pressures and electrical activity (electromyography or EMG). Subjects will be asked to sit on a commode, contract (squeeze) your anal muscles, blow into a balloon, and expel the paste into the commode.

06

What researchers measure

Primary outcomes

  1. Rectal emptying

    Measured by fecomanoflowmetry calculating the mean and maximum flow rate in various conditions (mg/sec), defecated volume (mg), flow time (sec) and time to maximum flow (sec). The amount of artificial stool evacuated is expressed in milligrams. The duration is in seconds. These 2 metrics are integrated to measure mg evacuated/second.

    Time frame: Baseline

  2. Rectoanal pressures

    Measured by anorectal manometry in mmHg

    Time frame: Baseline

Secondary outcomes

  1. Anal sphincter electromyography (EMG)

    Units - mV

    Time frame: Baseline

  2. Rectal compliance measured with a barostat

    Pressure (mmHg) corresponding to half-maximum rectal volume during rectal distention

    Time frame: Baseline

  3. Rectal Capacity measured with a barostat

    Rectal volume (ml) at maximum distending pressure during rectal distention

    Time frame: Baseline

  4. Rectal contractile response to distention measured with a sinusoidal oscillator

    Rectal balloon is inflated to a preload volume of 125ml. The balloon is then oscillated around baseline volume by 25mL for 20 min at a frequency of 5 counts per minute (cpm). The mean rectal pressure (cm H2O) will be calculated over the multiple oscillation cycles within the 20 minute distention segment.

    Time frame: Baseline

  5. Rectal sensory threshold for first sensation to defecate using barostat balloon distention

    The sensory threshold for first sensation to defecate is measured by stepwise inflation of the balloon (0-44 mm Hg, at 4 mm Hg increments). During this assessment participants are asked to report when they have the first sensation to defecate.

    Time frame: Baseline

  6. Rectal sensory threshold for desire to defecate using barostat balloon distention

    The sensory threshold for desire to defecate is measured by stepwise inflation of the balloon (0-44 mm Hg, at 4 mm Hg increments). During this assessment participants are asked to report when they have the desire to defecate.

    Time frame: Baseline

  7. Rectal sensory threshold for maximum urgency during barostat balloon distention

    The sensory threshold for maximum urgency to defecate is measured by stepwise inflation of the balloon (0-44 mm Hg, at 4 mm Hg increments). During this assessment participants are asked to report when they have the maximum urgency to defecate.

    Time frame: Baseline

  8. Rectal balloon expulsion time

    During this test, the time (seconds) required to expel a water-filled rectal balloon (50 ml) will be compared between healthy people and patients

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2019 (actual). Primary completion is estimated for Dec 2028, 119 months after the start.

Of 243 non-industry interventional studies with no phase under Constipation, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 35. This study's planned 119 months is above that.

Counting every sponsor, half of 314 studies reached it within 14 months; a quarter within 6 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2019
First posted
Feb 15, 2019
StartActual
Jan 29, 2019
Primary completionEst.
Dec 2028
CompletionEst.
Jun 2029
Last update
Aug 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03842007
Lead sponsor
Mayo Clinic
Responsible party
Adil Bharucha, MBBS, MD (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Feb 15, 2019
Start date
Jan 29, 2019
Primary completion
Dec 2028 (estimated)
Completion
Jun 2029 (estimated)
Last update
Aug 21, 2026

Study contacts

Kelly J Feuerhak
Contact
Feuerhak.Kelly@mayo.edu
507-255-6802
Adil E Bharucha, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion